Germany, March 23, 2021 – VSY Biotechnology, leading ophthalmic and orthopedic medical device and biotechnology company, announces the appointment of seasoned executive leader Can Ongen to the company’s Board of Directors. In this role, Can Ongen will also lead VSY Biotechnology’s sales and marketing activities with a view to further strengthening the company’s position worldwide. Can brings over 25 years of global leadership experience in medical devices, surgical implants, capital equipment, consumer and pharmaceuticals, having served in senior executive global commercial and marketing roles for Alcon and Galderma.
“We are delighted to welcome Can to our Board of Directors.” said Mr. Ercan Varlibas, Chairman of the Board of VSY Biotechnology. “Can is ideally suited to help us achieve our ambitious growth strategy. His extensive experience in successfully accomplishing sustainable growth and business expansion will be a tremendous asset as we seek to strengthen the global business of VSY Biotechnology.”
In his recent role as Vice President International Markets at Galderma (formerly known as Nestlé Skin Health), Mr. Ongen was one of the key executive players to turn around the company and ensure its successful sale to a private equity firm. Previously, his eye care expertise was established over 20 years in several global leadership roles with eye care product company, Alcon.
“Can’s appointment further strengthens our Board, and his commercial expertise will be of tremendous value to the team” added Mr. Ercan Varlibas.
On his appointment, Mr. Ongen commented, “I am truly excited to join the Board of VSY Biotechnology as they further develop their global vision and continue to develop, design and manufacture state-of-the-art products to serve doctors, patients and consumers worldwide. I look forward to contributing to the company’s sustainable growth strategy through the expertise I have acquired over many years in the pharmaceutical, medical device and consumer health sectors.”